DK0686044T3 - Hæmning af intimal hyperplasi under anvendelse af antistoffer mod PDGF-receptorer - Google Patents

Hæmning af intimal hyperplasi under anvendelse af antistoffer mod PDGF-receptorer

Info

Publication number
DK0686044T3
DK0686044T3 DK94909627T DK94909627T DK0686044T3 DK 0686044 T3 DK0686044 T3 DK 0686044T3 DK 94909627 T DK94909627 T DK 94909627T DK 94909627 T DK94909627 T DK 94909627T DK 0686044 T3 DK0686044 T3 DK 0686044T3
Authority
DK
Denmark
Prior art keywords
intimal hyperplasia
inhibition
antibodies against
pdgf
receptor antibody
Prior art date
Application number
DK94909627T
Other languages
English (en)
Inventor
Richard D Kenagy
Alexander W Clowes
Charles E Hart
Original Assignee
Zymogenetics Inc
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, Univ Washington filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of DK0686044T3 publication Critical patent/DK0686044T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK94909627T 1993-02-25 1994-02-17 Hæmning af intimal hyperplasi under anvendelse af antistoffer mod PDGF-receptorer DK0686044T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2350493A 1993-02-25 1993-02-25
PCT/US1994/001611 WO1994019016A1 (en) 1993-02-25 1994-02-17 Inhibition of intimal hyperplasia using antibodies to pdgf receptors

Publications (1)

Publication Number Publication Date
DK0686044T3 true DK0686044T3 (da) 2000-10-09

Family

ID=21815476

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94909627T DK0686044T3 (da) 1993-02-25 1994-02-17 Hæmning af intimal hyperplasi under anvendelse af antistoffer mod PDGF-receptorer

Country Status (8)

Country Link
EP (1) EP0686044B1 (da)
JP (1) JP2944218B2 (da)
AT (1) ATE170402T1 (da)
CA (1) CA2156825C (da)
DE (1) DE69413009T2 (da)
DK (1) DK0686044T3 (da)
ES (1) ES2122248T3 (da)
WO (1) WO1994019016A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252929B2 (en) 1989-02-09 2007-08-07 United States Of America, As Represented By The Secretary, Dept Of Health & Human Services Methods for identifying alpha PDGFR agonists and antagonists
US6228600B1 (en) 1992-07-20 2001-05-08 The United States Of America As Represented By The Department Of Health And Human Services Immunoassays for the alpha platelet-derived growth factor receptor
US5976534A (en) * 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US5882644A (en) * 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
WO1998035697A1 (en) * 1997-02-14 1998-08-20 Roche Diagnostics Gmbh Improved method for the reduction of neointima formation after angioplasty
AU1454199A (en) * 1997-11-07 1999-05-31 Massachusetts Institute Of Technology Pdgf-mediated microvascular communication and methods of use thereof
JP2003520830A (ja) 2000-01-25 2003-07-08 エドワーズ ライフサイエンシーズ コーポレイション 再狭窄および吻合内膜過形成処置のための送達系
US6990848B2 (en) * 2002-08-05 2006-01-31 Trxoler Electronic Laboratories, Inc. System and method for determining material properties of samples
CA2612449A1 (en) 2005-06-17 2006-12-28 Imclone Systems Incorporated Receptor antagonists for treatment of metastatic bone cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0619738B1 (en) * 1991-12-02 2003-07-09 Millennium Pharmaceuticals, Inc. Inhibitory immunoglobulin polypeptides to human pdgf beta receptor

Also Published As

Publication number Publication date
EP0686044B1 (en) 1998-09-02
JP2944218B2 (ja) 1999-08-30
WO1994019016A1 (en) 1994-09-01
ATE170402T1 (de) 1998-09-15
ES2122248T3 (es) 1998-12-16
EP0686044A1 (en) 1995-12-13
DE69413009D1 (de) 1998-10-08
CA2156825A1 (en) 1994-09-01
CA2156825C (en) 2003-10-21
JPH08507063A (ja) 1996-07-30
DE69413009T2 (de) 1999-03-25

Similar Documents

Publication Publication Date Title
DK0801572T3 (da) Sammensætning til inhibering af intimal hyperplasi ved anvendelse af PDGF-antagonister og heparin
DK0835115T3 (da) 4-(2-(N-2-carboxamidoindo)aminoethyl)-benzensulfonamider eller -sulfonylurinstoffer som PDGF-antagonister
EA200200503A1 (ru) Способ лечения ревматоидного артрита
DK0686044T3 (da) Hæmning af intimal hyperplasi under anvendelse af antistoffer mod PDGF-receptorer
ATE254631T1 (de) Pretargeting verfahren und mitteln
DK0673255T3 (da) Monoklonale antistoffer, som specifikt binder til vaskulært tumorendotel, og anvendelser deraf
ITTO930940A1 (it) Innesto protesico vascolare
FI961285A0 (fi) CD40:n vasta-aineita
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
ATE230020T1 (de) Katalytische antikörperkomponente
BR9913533A (pt) Processos para tratar hipertensão e composições para uso nos mesmos
DE69915977D1 (de) Neuartige Heparin bindende Peptide
EP1082069A4 (en) VASCULAR TREATMENTS OBTAINED BY VASTENING EXPANSION
DK0831807T3 (da) Anvendelse af Brefeldin A og derivater deraf til fremstilling af lægemidler til behandling af hyperplasia og beslægtede lidelser
ES2196150T3 (es) Induccion de tolerancia inmunologica por el uso de anticuerpos anti-cd4 que no inducen deplecion.
ES2054484T3 (es) Composiciones farmaceuticas que contienen complejos de antigeno-anticuerpo, asi como la utilizacion de las mismas.
ATE169227T1 (de) Hemmung von gefässverengung unter verwendung von anti-padgem antikörpern.
FI930265A0 (fi) Antikoagulantpeptider
MX9400204A (es) Composicion farmaceutica para reducir los niveles del factor reumatoide.
ES2097160T3 (es) Anticuerpos monoclonales anti-oncostantina m.
DE69326347D1 (de) Neuartiges endothelzell-molekül, das die bindung von lymphozyten im menschen vermittelt
DK0610447T3 (da) CDw52-specifikt antistof til behandling af T-cellemedieret inflammation af leddene
FR2697154B1 (fr) Perfectionnement au composant fémoral des prothèse du genou.
MX9102586A (es) Composicion de resina poli acetalica. composicion de resina poliacetalica.
FR2700264B1 (fr) Composant tibial pour prothèse monocompartimentale de genou cimentée.